In a landmark study published in the Proceedings of the National Academy of Sciences (PNAS), researchers from Northwestern University and Rockefeller University discovered that delivering a tiny genetic molecule called microRNA-205 (miR-205) can restart hair growth by physically “softening” stiff hair stem cells.
Biotechnology firm Amplifica Holdings Group is advancing a groundbreaking biological drug candidate called AMP-601, which utilizes a naturally occurring messenger protein to instruct dormant scalp stem cells to grow new hair.
Biotechnology firm HCW Biologics has announced clinical progress in its Phase 1 trial evaluating HCW9302, a first-in-kind injectable biological therapy for severe alopecia areata.
A novel oral drug candidate called ATI-2138 is showing remarkable speed in reversing severe autoimmune hair loss by targeting two distinct immune enzymes simultaneously.
Priovant Therapeutics has officially launched the seamless Phase 2b/3 ALPINE clinical trial for brepocitinib, evaluating the oral drug in adults with Lichen Planopilaris (LPP)—a severe, scarring form of hair loss that currently has no FDA-approved treatments.
Eli Lilly and Company has released three-year (152-week) long-term extension data from its landmark BRAVE-AA clinical trial program, demonstrating that the oral medication baricitinib (Olumiant) delivers durable, multi-year hair restoration for adults with severe alopecia areata.
A major clinical update in regenerative dermatology has confirmed that Acorn YOU™ autologous follicle secretome therapy offers a powerful, personalized solution for thinning hair without relying on synthetic drugs or donor surgeries.
Stemson Therapeutics has achieved a monumental milestone in regenerative medicine by demonstrating that 100% human, stem cell-derived hair follicles can be grown in human skin tissue.
In an exciting update for gene-silencing therapeutics, South Korean biotechnology company OliX Pharmaceuticals has advanced its lead hair loss candidate, OLX104C, through ongoing Phase 1b/2a clinical trials in Australia.
A revolutionary small-molecule compound called KY19382 is showing game-changing potential for treating pattern baldness by accomplishing what was long thought impossible: creating brand-new hair follicles from scratch. Developed as an advanced indirubin derivative, this topical treatment works by releasing a natural “handbrake” on your scalp’s hair-creation pathways.
A landmark six-month, double-blind, randomized, placebo-controlled clinical trial published in Clinical & Experimental Dermatology and Therapies has verified that a weekly RNA-interference tonic called CosmeRNA ARI significantly increases terminal hair density and reduces hair shedding in European adults with pattern baldness.
A major multi-center study evaluating intradermal dutasteride mesotherapy has confirmed that injecting low doses of the potent 5-alpha-reductase inhibitor directly into the scalp produces dramatic hair regrowth while completely avoiding systemic side effects.
Long-term clinical data presented at the European Academy of Dermatology and Venereology (EADV) Congress demonstrates that ritlecitinib (Litfulo) provides unprecedented multi-year durability for adults and adolescents suffering from severe alopecia areata.
On July 15, 2026, late-stage biopharmaceutical firm Veradermics announced positive topline results from the female treatment arms of its Phase 2 clinical trial (Study 207) evaluating its highly anticipated hair loss pill, VDPHL01.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has officially approved deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults, marking a major milestone for patients in the United Kingdom. Developed by Sun Pharma, this daily oral medication uses a highly precise biological pathway to silence the overactive immune signals that cause hair loss, allowing follicles to restart their natural growth cycle. In two pivotal Phase 3 clinical trials involving over 1,200 participants, the drug delivered remarkable regrowth, with approximately 30% of patients experiencing 80% or more scalp hair coverage after 24 weeks of treatment.
On July 15, 2026, late-stage biopharmaceutical firm Veradermics announced positive topline results from the female treatment arms of its Phase 2 clinical trial (Study 207) evaluating its highly anticipated hair loss pill, VDPHL01. Marking a historic step forward as a potential first-of-its-kind oral option specifically approved for female pattern hair loss, the drug achieved a rapid onset of activity, helping up to 90% of female participants experience “improved” or “much improved” hair coverage by Month 6.
A groundbreaking study published on April 20, 2026, has revealed that a natural flower extract from Ageratum houstonianum and its active compound, agerarin, can significantly regrow hair by boosting a vital “messenger protein” called SCUBE3.
On June 24, 2026, clinical-stage biopharmaceutical leader Absci Corporation announced positive interim Phase 1 clinical trial results for its generative AI-designed hair loss treatment, ABS-201. This groundbreaking therapy blocks the prolactin receptor in the scalp to release the “emergency brake” on stalled hair follicles, with the newly released data showing a massive 65-day half-life in humans. This means patients could potentially maintain continuous, robust hair regrowth with just two or three simple injections over an entire six-month period—offering a highly durable, low-maintenance alternative to daily pills or messy topical foams.
A Local Anti-Androgen Shield Completes its Final Human Trials: In March and June 2026, researchers released highly anticipated Phase 3 results for a novel topical treatment called KX-826 (Pyrilutamide). This represents a major milestone because it is a “first-in-class” therapy designed to block hair-loss hormones directly on the scalp without affecting the rest of the body’s hormone levels. Having successfully met its primary endpoints in a pivotal late-stage trial, this treatment is now moving toward official regulatory submission, promising a highly effective, non-systemic alternative to traditional hair loss medications.
Scientists have officially moved a highly advanced genetic therapy called ALY-101 into human clinical trials. This is a massive breakthrough because it represents the first-ever use of RNA interference (siRNA) to treat hair loss. Instead of using daily pills that suppress the entire immune system, this treatment uses a single biological molecule injected into the scalp to temporarily “mute” the specific gene responsible for triggering hair loss.
Topical Deoxyribose-Mediated Upregulation of Vascular Endothelial Growth Factor (VEGF) and Angiogenesis Achieves 80% to 90% of Minoxidil’s Regrowth Efficacy in Preclinical Studies and Launches First Human Comparative Clinical Trials.
A biotechnology company has presented clinical trial results for a new biological treatment called bempikibart (also known as ADX-914). For the first time in the history of autoimmune hair loss research, scientists have demonstrated a treatment that continues to regrow and maintain scalp hair long after the patient has stopped taking the drug, pointing toward a true “remission” rather than a lifetime of daily therapy.
A biotechnology company has announced highly successful results from the first human trial of a new rub-on treatment called ET-02. Rather than using hormones or harsh chemicals, this liquid works by fixing the internal “biological glitch” that causes hair follicles to stop working as we age.
Topical Upregulation of Vascular Endothelial Growth Factor (VEGF) and Stimulation of Neovascularization via 2-Deoxy-D-Ribose (2dDR) Sugar Gel: 80% to 90% as Effective as Minoxidil in Triggering Robust Hair Regrowth.
Targeted Subcutaneous Injection of Autologous Growth Factor Concentrate: Complete Elimination of Active Hair Shedding and Significant Improvement in Hair Density in 8 Weeks.
Scientists have just published the results of a major clinical trial comparing the popular hair loss treatment, Platelet-Rich Plasma (PRP), to its next-generation upgrades: i-PRF (injectable Platelet-Rich Fibrin) and CGF (Concentrated Growth Factors). The new treatments proved to be nearly twice as effective at regrowing hair for women experiencing thinning hair.
Scientists have discovered a crucial protein called MCL-1 that acts as a biological “bodyguard” to keep hair stem cells alive during their high-stress growth phase. When hair follicles wake up to grow new hair, the intense pressure on their DNA and energy systems can trigger a self-destruct pathway. Clinical experiments published in Nature Communications show that without this bodyguard protein, hair stem cells completely die off, leading to permanent hair loss, while stabilizing MCL-1 allows them to repair and regrow hair safely.
SinoMab BioScience has presented promising preclinical data for its Anti-CGC Antibody (hC2) at the Society for Investigative Dermatology (SID) 2026 Annual Meeting. In humanized animal models of alopecia areata, hC2 administration significantly reduced hair loss by blocking the common gamma chain receptor, which acts as the main gateway for inflammatory cytokines.
The clinical candidate causing some excitement for application in androgenetic alopecia is PP405, an investigational medicine developed by Pelage Pharmaceuticals. Presentations at the AAD 2026 meeting in Denver and the SID meeting in Chicago highlight PP405 as the first therapy to successfully target dormant hair follicle stem cells directly at the level of their metabolism.
The most anticipated update from the SID 2026 meeting is the presentation by Dr. Peggy Myung, Associate Professor and Vice Chair of Research in the Department of Dermatology at Yale University. In her State-of-the-Art Plenary Lecture, “Uncovering mechanisms of hair follicle dermal niche formation in development and regeneration,” Dr. Myung unveiled the molecular roadmap for creating hair follicles from scratch in adult skin.